AMERICAN SOCIETY OF CLINICAL ONCOLOGY

AbbVie submits BLA for Teliso-V, an ADC targeting c-Met overexpression in previously treated nonsquamous NSCLC, with data from Phase 2 LUMINOSITY trial. Teliso-V could be the first-in-class therapy for this patient population.

ImPact Biotech's Phase 3 ENLIGHTED trial for Padeliporfin VTP in low-grade UTUC achieved 50% enrollment, with full enrollment expected by Q1 2025. Interim results show 77% CR in response-evaluable patients, supported by EIC investment.

AstraZeneca's Tagrisso (osimertinib) approved in the US for treating unresectable, Stage III EGFRm NSCLC, reducing disease progression risk by 84% compared to placebo. The approval is based on the LAURA phase III trial results, showing a median PFS of 39.1 months with Tagrisso versus 5.6 months for placebo. The trial continues to assess overall survival.

ImPact Biotech's Phase 3 ENLIGHTED trial achieved 50% enrollment for Padeliporfin VTP therapy in low-grade UTUC patients, with interim results showing 77% CR rate. The study is expected to complete enrollment by Q1 2025, supported by substantial investment from the European Innovation Council.

AstraZeneca's TAGRISSO® (osimertinib) approved in the US for treating unresectable, Stage III EGFRm NSCLC patients who haven't progressed post-CRT. TAGRISSO reduced disease progression risk by 84% in LAURA Phase III trial, extending median PFS to 39.1 months.

Oncology research nurses collect data during clinical trials, assess adverse events, and support new cancer therapy development. They differ from traditional nurses by focusing on data that may lead to new FDA-approved treatments. Key responsibilities include screening patients, administering medication, and ensuring protocol adherence. Balancing patient care with research protocols requires thorough preparation. Effective communication with patients and collaboration with healthcare professionals are crucial. Professional development opportunities include attending conferences and obtaining research certifications. The most rewarding aspect is seeing patients respond positively to treatment.

AbbVie submits Biologics License Application to FDA for Teliso-V, an investigational treatment for previously treated non-small cell lung cancer with c-Met overexpression.

FDA approves AstraZeneca's Tagrisso for unresectable, Stage III EGFR-mutated lung cancer, based on LAURA Phase III trial results showing 84% reduction in disease progression risk.

Osimertinib (Tagrisso) received FDA approval for unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutations, based on LAURA trial data showing significant benefits, including 39.1-month median progression-free survival.